Sonnet Biotherapeutics Holdings Inc (NASDAQ:SONN) — Stock Price
Sonnet Biotherapeutics Holdings Inc (NASDAQ:SONN) is currently trading at $1.26 USD, down 59.35% today. Over the past 52 weeks, shares have ranged between $1.26 and $7.58. This page tracks Sonnet Biotherapeutics Holdings Inc's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see SONN market cap.
Sonnet Biotherapeutics Holdings Inc (SONN) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Sonnet Biotherapeutics Holdings Inc's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Sonnet Biotherapeutics Holdings Inc Income Statement — Revenue, Profit & Earnings by Year
Sonnet Biotherapeutics Holdings Inc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $1.00 Million | $18.63K | $147.81K | $349.94K | $483.63K |
| Cost of Revenue | — | $83.11K | $75.75K | $93.26K | $95.16K |
| Gross Profit | — | $18.63K | $147.81K | $-21.09 Million | $483.63K |
| Research & Development | $8.36 Million | $5.74 Million | $11.81 Million | $21.44 Million | $16.63 Million |
| SG&A | $8.49 Million | $6.13 Million | $7.13 Million | $8.58 Million | $8.94 Million |
| Total Operating Expenses | $16.84 Million | $11.87 Million | $18.94 Million | $8.58 Million | $25.57 Million |
| Operating Income | $-15.84 Million | $-11.85 Million | $-18.79 Million | $-29.67 Million | $-25.09 Million |
| EBITDA | $-15.84 Million | $-11.77 Million | $-18.72 Million | $-29.58 Million | $-24.99 Million |
| EBIT | — | $-11.85 Million | $-18.79 Million | $-29.67 Million | $-25.09 Million |
| Interest Expense | — | — | — | $40.77K | $0.00 |
| Income Before Tax | $-15.79 Million | $-7.44 Million | $-18.83 Million | $-29.72 Million | $-24.98 Million |
| Income Tax Expense | $-218.40K | — | $40.08K | $52.48K | $22.03K |
| Net Income | $-16.11 Million | $-7.44 Million | $-18.83 Million | $-29.77 Million | $-25.01 Million |
Sonnet Biotherapeutics Holdings Inc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Sonnet Biotherapeutics Holdings Inc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $14.88 Million | $2.77 Million | $5.43 Million | $5.83 Million | $28.99 Million |
| Total Current Assets | $14.34 Million | $2.12 Million | $4.74 Million | $5.41 Million | $28.81 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | — | $762.08K | $786.57K | $717.30K | — |
| Inventory | — | — | — | $-717.30K | — |
| Property, Plant & Equipment | — | — | — | $302.81K | $182.27K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $4.10 Million | $3.26 Million | $5.66 Million | $8.37 Million | $6.73 Million |
| Total Current Liabilities | $4.10 Million | $3.21 Million | $5.52 Million | $8.16 Million | $6.70 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-5.07 Million | $-18.59K | $-2.07 Million | $-2.80 Million | $-27.50 Million |
| Total Stockholder Equity | $10.79 Million | $-485.74K | $-225.98K | $-2.54 Million | $22.26 Million |
| Retained Earnings | $-133.69 Million | $-117.68 Million | $-110.24 Million | $-91.41 Million | $-61.69 Million |
Sonnet Biotherapeutics Holdings Inc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Sonnet Biotherapeutics Holdings Inc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-12.83 Million | $-8.61 Million | $-21.34 Million | $-27.69 Million | $-22.55 Million |
| Capital Expenditures | $0.00 | $3.00 | $443.25K | $896.48K | $3.62K |
| Free Cash Flow | $-12.83 Million | $-8.61 Million | $-21.79 Million | $-28.58 Million | $-22.56 Million |
| Investing Cash Flow | $-12.00K | $-12.00K | $-443.25K | $-896.48K | $-3.62K |
| Financing Cash Flow | $26.05 Million | $6.49 Million | $21.01 Million | $4.01 Million | $42.83 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $199.59K | $231.19K | $248.63K | $876.37K | $1.38 Million |
| Depreciation | $89.26K | $83.11K | $75.75K | $93.26K | $95.16K |
| Change in Cash | $13.21 Million | $-2.12 Million | $-778.62K | $-24.57 Million | $20.27 Million |
Sonnet Biotherapeutics Holdings Inc Earnings History — EPS Actual vs. Analyst Estimates
Track Sonnet Biotherapeutics Holdings Inc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 13, 2025 | -0.95 | -0.49 | -93.88% |
| May 12, 2025 | -0.89 | -0.92 | +3.26% |
| Feb 12, 2025 | -1.56 | -11.12 | +85.97% |
| Dec 12, 2024 | -10.39 | -5.52 | -88.22% |
| Aug 14, 2024 | -0.70 | -0.76 | +7.89% |
| May 14, 2024 | 0.07 | 0.14 | -50.00% |
| Feb 14, 2024 | -0.31 | -0.90 | +65.56% |
| Dec 14, 2023 | -2.09 | -4.09 | +48.90% |